Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 50Carcinoma, Non-Small-Cell Lung 36Ovarian Neoplasms 35Stomach Neoplasms 32Esophageal Neoplasms 29Uterine Cervical Neoplasms 21Esophageal Squamous Cell Carcinoma 19Fallopian Tube Neoplasms 16Lung Neoplasms 13Carcinoma, Ovarian Epithelial 13Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9Triple Negative Breast Neoplasms 8Recurrence 8Neoplasm Metastasis 6Endometrial Neoplasms 6Advanced Gastric Cancer 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Nasopharyngeal Neoplasms 5Hypopharyngeal Neoplasms 4Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Carcinoma 3Anus Neoplasms 3Adenocarcinoma Of Esophagus 3

Interventions

Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Paclitaxel × Clear all
NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
492 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡